BiotechTube

Efanesoctocog alfa

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

May 21, 2025 → Dec 1, 2028

NCT ID
NCT06940830

About Efanesoctocog alfa

Efanesoctocog alfa is a approved stage product being developed by Swedish Orphan Biovitrum for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06940830. Target conditions include Hemophilia A.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (5)

NCT IDPhaseStatus
NCT06940830ApprovedRecruiting
NCT06716814Phase 3Recruiting
NCT06579144Phase 1Recruiting
NCT06752850ApprovedActive
NCT05817812Phase 3Active

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
77
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
77
EmicizumabRochePhase 3
77
HEMLIBRAJohnson & JohnsonPre-clinical
23
EmicizumabRochePhase 3
77
EmicizumabRocheApproved
85
EmicizumabRochePhase 3
77
SPK-8011QQRochePhase 1/2
41
NXT007RochePhase 1/2
41
Emicizumab InjectionRochePhase 2
52
Bypassing Agents + FVIII ReplacementRochePre-clinical
23
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
51
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
22
Refacto AFPfizerPre-clinical
22
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
76
ReFacto AFPfizerPhase 3
76

Other Products from Swedish Orphan Biovitrum

Recombinant coagulation factor (rFVIIIFc)Approved
84
rFVIIIFcApproved
84
AnakinraApproved
84
Kepivance (Palifermin)Approved
84
Emapalumab-Lzsg 5 MG/ML [Gamifant]Approved
84